Calreticulin (CALR) is an endoplasmic reticulum (ER)-resident protein involved in a
spectrum of cellular processes. In healthy cells, CALR operates as a chaperone and Ca2+ …

The genetic landscape of classical myeloproliferative neoplasm (MPN) is in large part
elucidated. The MPN-restricted driver mutations, including those in JAK2, calreticulin …

Defining the transcriptomic identity of malignant cells is challenging in the absence of
surface markers that distinguish cancer clones from one another, or from admixed non …

Abstract During SARS-CoV-2 infection, the innate immune response can be inhibited or
delayed, and the subsequent persistent viral replication can induce emergency signals that …

Bone marrow fibrosis (BMF) develops in various hematological and non-hematological
conditions and is a central pathological feature of myelofibrosis. Effective cell-targeted …

The JAK–STAT signal transduction pathway is responsible for mediating signals of over fifty
cytokines, growth factors and hormones. Signaling through the JAK–STAT pathway is …

Myeloid neoplasms, including acute myeloid leukemia (AML), myeloproliferative neoplasms
(MPNs), and myelodysplastic syndromes (MDS), feature clonal dominance and remodeling …

Substantial progress has been made in our understanding of the pathogenetic basis of
myeloproliferative neoplasms. The discovery of mutations in JAK2 over a decade ago …

Myeloproliferative neoplasms (MPNs) arise in the hematopoietic stem cell (HSC)
compartment as a result of the acquisition of somatic mutations in a single HSC that provides …

JAK inhibitors have been developed following the discovery of the JAK2V617F in 2005 as
the driver mutation of the majority of non-BCR-ABL1 myeloproliferative neoplasms (MPNs) …